Monthly weight loss drug helps people lose 20% of body weight, trial finds

Amgen’s monthly weight loss drug MariTide demonstrated a 20% average body weight reduction in a phase 2 trial, positioning it as a potential competitor in the GLP-1 market dominated by Novo Nordisk and Eli Lilly. With added benefits like improved A1c levels and cardiovascular risk factors, MariTide aims for a phase 3 trial, highlighting advancements in diabetes and weight loss treatments.

Need More Context? 🔎